RON HOOGEVEEN to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications RON HOOGEVEEN has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
0.503
-
LDL and HDL subfractions, dysfunctional HDL: treatment options. Curr Pharm Des. 2014; 20(40):6249-55.
Score: 0.273
-
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015 Jan 24; 385(9965):351-61.
Score: 0.072
-
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis. 2014 Jan; 232(1):86-93.
Score: 0.067
-
Role of lipid and lipoprotein profiles in risk assessment and therapy. Am Heart J. 2003 Aug; 146(2):227-33.
Score: 0.033
-
ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change. Neurology. 2019 05 28; 92(22):e2580-e2593.
Score: 0.025
-
Plasma Levels of Endothelial Microparticles Bearing Monomeric C-reactive Protein are Increased in Peripheral Artery Disease. J Cardiovasc Transl Res. 2016 06; 9(3):184-193.
Score: 0.020
-
Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study. Eur Heart J. 2011 Feb; 32(4):459-68.
Score: 0.014